THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-brokered private placement (the "Offering") previously announced on Wednesday, September 23, 2026. The Upsized Offering will include up to C$600,000 in unsecured convertible debentures (each, a "Debenture") and up to C$1,000,000 in units (each, a "Unit") for aggregate gross proceeds of up to C$1,600,000. Each Unit will consist of one common share of the Company (each, a "Share") and one Share purchase warrant of the Company (each, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one additional Share at a price of C$1.00 at any time on or before the date which is 18 months after the closing date of the Upsized Offering. The Debentures issued under the Upsized Offering will bear interest at a rate of 10% per annum, calculated monthly and payable quarterly in cash. The Debentures will mature on the one-year anniversary following the date of issuance. The outstanding principal amount owed under a Debenture may be converted into Share at a conversion price of $0.50 per Share (the "Conversion Price") by the holder thereof at any time on or before the Maturity Date. On the Maturity Date, the holders of the Debentures may convert the outstanding principal amount, together with any accrued and unpaid interest thereon, into Shares at the Conversion Price. The proposed use of proceeds from the Upsized Offering is to fund new inventory, product development, and to scale the sales and marketing division globally, as well as general working capital. All securities issued in connection with the Upsized Offering will be subject to a statutory hold period of four months and one day following the date of issuance in accordance with applicable Canadian securities laws. The Upsized Offering is subject to approval by the CSE and the filing of all required documentation. The securities of the Company referred to in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful. About TempraMed Technologies Ltd. TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered thermal insulation devices that work 24/7 without batteries or external power. With a product line already in market including VIVI Cap™, VIVI Cap Smart™, VIVI Epi™ and VIVI Med™, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe and Asia, TempraMed continues to expand globally with solutions for medication protection and adherence. Investors interested in learning more about TempraMed are encouraged to contact the Company at: ir@tempramed.comwww.tempramed.comContact Julia Becker Vice President, Capital Markets T: +1 (604) 785-0850 E: julia@tempramed.comMedia Brenda Zeitlin Vice President, Marketing E: brenda@tempramed.comCautionary Statement Regarding "Forward-Looking" Information This News Release includes certain "forward-looking statements" which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", "likely", "probably", "often", or "plan". Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management's expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results,...